CTLA4 and neoplasm: This hypothesis is tested in the current study, in which the immunotherapy-refractory murine orthotopic pancreatic KPC tumour model was used to investigate whether pHIFU can induce mechanical damage in orthotopic pancreatic tumours to enhance the anti-cancer effects of anti-CTLA-4 and anti-PD-1 ICIs.